Does Mitapivat Interact with Sensitive Cyp3a Substrates With Narrow Therapeutic Index?
CDI records a contraindicated classification for Mitapivat and Sensitive Cyp3a Substrates With Narrow Therapeutic Index. The stored summary is: PYRUKYND induces CYP3A, decreasing concentrations of sensitive substrates with narrow therapeutic index. Avoid concomitant use. The mechanism involves cyp3a induction. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Contraindicated
- Mitapivat Class
- Pyruvate Kinase Activator
- Management
- Do not take together
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
CYP3A induction
What To Tell Your Doctor or Pharmacist
If you are taking Mitapivat and your doctor is considering prescribing Sensitive Cyp3a Substrates With Narrow Therapeutic Index (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask about alternative medications that do not interact with your current regimen
- Ask how frequently you should be monitored while these are co-prescribed
- Never stop or change either medication without first consulting your healthcare provider